Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis

BACKGROUND: In Ontario, FOLFIRINOX (FFX) and gemcitabine + nab‐paclitaxel (GnP) have been publicly funded for first‐line unresectable locally advanced pancreatic cancer (uLAPC) or metastatic pancreatic cancer (mPC) since April 2015. We examined the real‐world effectiveness and safety of FFX vs GnP f...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Kelvin K. W., Guo, Helen, Cheng, Sierra, Beca, Jaclyn M., Redmond‐Misner, Ruby, Isaranuwatchai, Wanrudee, Qiao, Lucy, Earle, Craig, Berry, Scott R., Biagi, James J., Welch, Stephen, Meyers, Brandon M., Mittmann, Nicole, Coburn, Natalie, Arias, Jessica, Schwartz, Deborah, Dai, Wei F., Gavura, Scott, McLeod, Robin, Kennedy, Erin D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943167/
https://www.ncbi.nlm.nih.gov/pubmed/31724340
http://dx.doi.org/10.1002/cam4.2705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943167/
https://www.ncbi.nlm.nih.gov/pubmed/31724340
http://dx.doi.org/10.1002/cam4.2705

Ejemplares similares